VivoSeq
Oncology

Diffuse Large B-Cell Lymphoma Activated B-Cell Type

6

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Diffuse Large B-Cell Lymphoma Activated B-Cell Type is an early-stage landscape with 6 programs across 2 companies. The most active players are Teva, Avyxa. 6 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Teva logo

Teva

1 program

Phase 3A

Avyxa

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 36

Carmustine

Melissa K Accordino

Cyclophosphamide

Baxter Healthcare Corporation

Cytarabine

Teva

Etoposide

Avyxa

Ibrutinib

Pharmacyclics LLC.

Approved
No programs

Analysis

Trial Status

1

clinical trials

Active, not recruiting1 · 100%

Clinical Trials

Trial Activity

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT02443077·94 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)